Clinical Trial Update: Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion [NA]

View source ↗

Summary

Clinical trial update on Integra Accell Evo3 DBM for instrumented lumbar spine fusion reports completed status with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Changes of Spine
• Degenerative Lumbar Stenosis
• Spondylosis

Drugs mentioned

• Integra Accell Evo3 DBM (bone graft material)

Snippet

Sponsor: SeaSpine, Inc. | Conditions: Stenosis, Spondylosis | NA | Status: COMPLETED | Results posted: 2017-12-20